Xencor Inc — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 71/100
What the filing says
Xencor and Alexion settled a commercial dispute over U.S. royalties on Ultomiris (ravulizumab-cwvz). Xencor will receive $105 million in two equal $52.5 million payments (first in August 2026, second one year later), and Alexion will owe no future U.S. royalties; ex-U.S. royalties continue unchanged. Xencor now projects sufficient cash to fund operations through 2028.
Why this rating
Settlement provides ~19% of company market cap in near-term cash, eliminates uncertainty, extends runway to 2028. Material but not transformational.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.